Author(s): Ahmed Mahmoud Abdelrahim*, Hassan Awwad, Azza Awad Abdel Razek, Mahmoud Mohamed Sobhy, Ahmed Elmaraghy
Background: Polycystic ovary syndrome: Abbreviated PCOS. Polycystic ovary syndrome is a condition in women characterized by irregular or no menstrual periods, acne, obesity, and excess hair growth. PCOS is a disorder of chronically abnormal ovarian function and hyperandrogenism (abnormally elevated androgen levels). In a non-PCOS population, BMI is known to affect in vitro fertilization (IVF) outcomes. Although weight reduction improves fertility in PCOS patients attempting spontaneous conception, studies of PCOS patients to date do not fully evaluate the impact of a range of BMIs on IVF outcomes. Aims: The aim of this study is to correlate between body mass index and gonadotrophin secretions in PCOS patients and their effect on clinical pregnancy in ICSI cycles. Methodology: The study was done in IVF unit at Maternity Hospital of Ain Shams University, the period of the study was from November 2017 to April 2018. A total of 96 women with history of PCOS and infertility enrolled in the study and divided into two groups, one of them 46 women with BMI ≥ 30 kg/m2 and the other 50 women with BMI < 30kg/m2. Results: There is a significant difference between the two groups in body mass index and duration of infertility. The clinical pregnancy rate was 37% in non-obese group while it was 33.3% in obese group, so obese group had non-significantly lower clinical pregnancy than non-obese group. Conclusion: PCOS is a broad syndrome, in the current study there is a comparison between two groups of women with PCOS undergoing ICSI, one of them was obese and the other was non obese. It was found that clinical pregnancy rate was more in the non-obese group, indicating that BMI could be correlated to the outcomes of ICSI. Recommendations: Obese PCOS patients are more likely than non-obese PCOS patients to have less clinical pregnancy rate after ICSI. Future studies might prospectively examine the effect of gonadotropin dose adjustments on clinical outcomes across a range of BMIs in PCOS patients. Multisite collaborations are needed to maximize sample size.